2. Search Result
Search Result
Results for "

Citrulline

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

2

Fluorescent Dye

7

Peptides

2

Inhibitory Antibodies

5

Natural
Products

1

Recombinant Proteins

6

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15575
    VcMMAE
    Maximum Cited Publications
    92 Publications Verification

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
    VcMMAE
  • HY-N0391
    L-Citrulline
    5+ Cited Publications

    		 Endogenous Metabolite Others
    L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline
  • HY-20336
    Mc-Val-Cit-PABC-PNP
    5+ Cited Publications

    Maleimidocaproyl-L-valine-L-Citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate

    		 ADC Linker Others Inflammation/Immunology Cancer
    Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .
    Mc-Val-Cit-PABC-PNP
  • HY-W142119
    α-Methyl-DL-aspartic acid
    4 Publications Verification

    		 Ser/Thr Protease Neurological Disease
    α-Methyl-DL-aspartic acid is a specific inhibitor of argininosuccinate synthase (ASS), and also is the rate-limiting enzyme for the recycling of 1-citrulline to 1-arginine .
    α-Methyl-DL-aspartic acid
  • HY-171265
    Becotatug vedotin

    MRG003

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
    Becotatug vedotin
  • HY-N0391S5
    L-Citrulline-d7

    		Isotope-Labeled Compounds Endogenous Metabolite Others
    L-Citrulline-d7 is the deuterium labeled L-Citrulline. L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline-d7
  • HY-P99829
    Cofetuzumab pelidotin

    PF-06647020; ABBV-647; h6M24-vc0101

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
    Cofetuzumab pelidotin
  • HY-W016733
    D-Citrulline

    H-D-Cit-OH

    		 Endogenous Metabolite Cardiovascular Disease
    D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
    D-Citrulline
  • HY-W018004
    L-Homocitrulline

    		Amino Acid Derivatives Endogenous Metabolite Inflammation/Immunology
    L-Homocitrulline is a carbamoylated derivative amino acid and a structural analog of L-citrulline. L-Homocitrulline serves not only as an intermediate in polypeptide synthesis but also converts into a variety of cyclic derivatives under enzymatic or acidic conditions. The level of L-Homocitrulline is significantly elevated in the serum of patients with non-alcoholic fatty liver disease (NAFLD), with high diagnostic accuracy. L-Homocitrulline also exists in patients with related diseases such as hypercitrullinemia. L-Homocitrulline is a key biomarker for monitoring abnormal liver metabolism and is widely used in NAFLD research .
    L-Homocitrulline
  • HY-N0391A
    L-Citrulline DL-malate
    5+ Cited Publications

    		 Endogenous Metabolite Others
    L-Citrulline (DL-malate) is an organic compound commonly used as a nutritional supplement. It boosts the body's production of nitrogen oxides, improves circulation and athletic performance, and reduces muscle fatigue. In addition, L-Citrulline DL-malate also plays an important role in some industrial fields, for example, it is used in the field of agriculture to enhance plant immunity.
    L-Citrulline DL-malate
  • HY-15575S
    VcMMAE-d8

    MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
    VcMMAE-d8
  • HY-N0391S4
    L-Citrulline-d4

    		Endogenous Metabolite Others
    L-Citrulline-d4 is the deuterium labeled L-Citrulline. L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline-d4
  • HY-N0391R
    L-Citrulline (Standard)

    		Reference Standards Endogenous Metabolite Others
    L-Citrulline (Standard) is the analytical standard of L-Citrulline. This product is intended for research and analytical applications. L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline (Standard)
  • HY-N0391S3
    L-Citrulline-13C

    		Endogenous Metabolite Others
    L-Citrulline- 13C is the 13C-labeled L-Citrulline. L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline-13C
  • HY-W008064
    Fmoc-Cit-OH

    Fmoc-L-Citrulline

    		 Amino Acid Derivatives Cancer
    Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .
    Fmoc-Cit-OH
  • HY-170534
    Ac-EEVC-OH

    		ADC Linker Cancer
    Ac-EEVC-OH is a ADC Linker that can be used for the synthesis of ADC molecules .
    Ac-EEVC-OH
  • HY-143678
    Citrulline-specific probe-biotin

    		Biochemical Assay Reagents Others
    Citrulline-specific probe-biotin is a biotinylated probe for detection of citrulline. Citrulline is the hydrolysis product of arginine catalyzed by protein arginine deiminase (PAD). PAD is abnormally activated in many diseases, leading to increased citrulline levels. Citrulline-specific probe-biotin is a biological probe that can identify diseases showing abnormal increases in PAD activity .
    Citrulline-specific probe-biotin
  • HY-P2966
    Protein-arginine deiminase

    		Endogenous Metabolite Metabolic Disease
    Protein-arginine deiminase is a unique family of enzymes that catalyzes the hydrolysis of peptidyl-arginine to form peptidyl-citrulline .
    Protein-arginine deiminase
  • HY-171572
    Atezolizumab-MMAE

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Apoptosis Inflammation/Immunology Cancer
    Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
    Atezolizumab-MMAE
  • HY-D1377
    Citrulline-specific probe-rhodamine hydrate

    		Fluorescent Dye Others
    Citrulline-specific probe-rhodamine hydrate is a specific probe for citrulline (Citrulline) combined with a rhodamine fluorescent group. Citrulline is the hydrolysis product of arginine catalyzed by protein arginine deiminase (PAD). PAD is abnormally activated in many diseases, leading to increased citrulline levels. Citrulline-specific probe-rhodamine hydrate is a biological probe that can identify diseases showing abnormal increases in PAD activity and may be effectively used in animal models of ulcerative colitis .
    Citrulline-specific probe-rhodamine hydrate
  • HY-N0391S2
    L-Citrulline-d6

    		Endogenous Metabolite Others
    L-Citrulline-d6 is the deuterium labeled L-Citrulline. L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline-d6
  • HY-138106
    Fmoc-D-Cit-OH

    		Amino Acid Derivatives Others
    Fmoc-D-Cit-OH is citrulline with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as H-Dmt-D-Cit-Aba-b-Ala-NMe-30,50-(CF3)2-Bn and H-Dmt-D-Cit-Aba-b-Ala-NMe-Bn with neurokinin-1 antagonist activity .
    Fmoc-D-Cit-OH
  • HY-W141765
    Fmoc-Cit-PAB-OH

    		Biochemical Assay Reagents Others
    Fmoc-Cit-PAB-OH is a peptide linker containing an Fmoc-protected amine and citrulline residue. The Fmoc group can be deprotected under basic conditions to obtain the free amine, which can be used for further conjugations.
    Fmoc-Cit-PAB-OH
  • HY-171734
    DEDN6526A

    		Antibody-Drug Conjugates (ADCs) Endothelin Receptor Microtubule/Tubulin Apoptosis Cancer
    DEDN6526A is an antibody-drug conjugate (ADC) consisting of the humanized anti-ETBR antibody DEDN6526A (RG-7636) (HY-P990573 conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (McMMAF) (HY-15575). DEDN6526A induces apoptosis and can be used in melanoma research .
    DEDN6526A
  • HY-CE01658
    L-Citrulline-CoA

    L-Citrulline-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    L-Citrulline-CoA (L-Citrulline-coenzyme A) is a coenzyme A derivative .
    L-Citrulline-CoA
  • HY-W698343
    NG-Hydroxy-L-arginine acetate

    NOHA acetate

    		 Arginase Endogenous Metabolite Others
    NG-Hydroxy-L-arginine acetate (NOHA acetate) serves as a physiological inhibitor of arginase, playing a crucial role in the conversion of arginine to nitric oxide and citrulline by nitric oxide synthase.
    NG-Hydroxy-L-arginine acetate
  • HY-115410
    NG-Amino-L-arginine hydrochloride

    		NO Synthase Metabolic Disease
    NG-Amino-L-arginine hydrochloride induces inactivation of the citrulline-forming activity of the nNOS, iNOS, and eNOS isoforms with Ki values of 0.3 μM, 3 μM, and 2.5 μM, respectively .
    NG-Amino-L-arginine hydrochloride
  • HY-171683
    Anti-CCL2 (Carlumab)-VcMMAE

    		Antibody-Drug Conjugates (ADCs) CCR Microtubule/Tubulin Apoptosis Cancer
    Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research .
    Anti-CCL2 (Carlumab)-VcMMAE
  • HY-N0391S6
    L-Citrulline-d2

    		Isotope-Labeled Compounds Endogenous Metabolite Others
    L-Citrulline-d2 is the deuterium labeled L-Citrulline (HY-N0391). L-Citrulline is an amino acid derived from ornithine in the catabolism of proline or glutamine and glutamate, or from l-arginine via arginine-citrulline pathway.
    L-Citrulline-d2
  • HY-CE01574
    N-Acetyl-L-citrulline-CoA

    N-Acetyl-L-ctrulline-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    N-Acetyl-L-citrulline-CoA (N-Acetyl-L-ctrulline-coenzyme A) is a coenzyme A derivative .
    N-Acetyl-L-citrulline-CoA
  • HY-E70954
    Peptidyl Arginine Deiminase, Rabbit

    		Protein Arginine Deiminase Metabolic Disease
    Peptidyl Arginine Deiminase, Rabbit (EC 3.5.3.15) is the enzyme that converts arginine into citrulline. Calcium is required for peptidylarginine deiminase activity in vitro.
    Peptidyl Arginine Deiminase, Rabbit
  • HY-B1713
    Ornithine

    (±)-Ornithine

    		 Endogenous Metabolite Ornithine decarboxylase (ODC) Drug Intermediate Metabolic Disease Cancer
    Ornithine ((±)-Ornithine) is a non-essential amino acid. Ornithine is an intermediate in urea cycle and acts as a substrate for these rate limiting enzymes ornithine transcarbomylase, ornithine aminotransferase and ornithine decarboxylase producing citrulline, proline and polyamines, respectively. Ornithine can be used in the research of hyperornithinemia, hyperammonemia, and cancer .
    Ornithine
  • HY-W591440
    Fmoc-Cit-PAB-PNP

    		Biochemical Assay Reagents Others
    Fmoc-Cit-PAB-PNP is a Citrulline linked to 4-aminobenzoiate (PAB) with terminal Fmoc and PNP groups. The Fmoc group can be deprotected under basic conditions to release the free amine which can be used for further conjugations. PNP group is a good leaving group when reacting with an amine-bearing payload.
    Fmoc-Cit-PAB-PNP
  • HY-160756
    Val-Cit-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
    Val-Cit-Exatecan
  • HY-P992098
    Adargiminase

    NEI-01

    		 Protein Arginine Deiminase Cancer
    Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer .
    Adargiminase
  • HY-142079
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma .
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: